Ukr.Biochem.J. 2017; Volume 89, Issue 3, May-Jun, pp. 31-35

doi: https://doi.org/10.15407/ubj89.03.031

Some biochemical changes in patients with acute ischemic stroke

24.05.2017   Uncategorized   No comments

O. Ja. Mykhalojko, І. Ja. Mykhalojko

Ivano-Frankivsk National Medical University, Ukraine;
e-mail: myhalojko@i.ua

The aim was to determine the alterations in levels of vasculair endothelial growth factor (VEGF), homocysteine (HC) and lipid profile in patients with acute ischemic stroke (AIS), to establish the relationship between them. A clinical and neurological examination of 120 patients aged 56 to 75 years with AIS was done. Diagnosis was established taking into account results of spiral computer and magnetic resonance tomography. The control group included 20 people with no signs of acute cerebrovascular and severe somatic pathology aged 59.35±1.8 years. Assessment of disability was performed at admission and during the treatment using the scale NIHSS. In all relevant patients in 1-2 days after stroke, the concentration of HC and VEGF levels was determined by ELISA. Blood lipid profile was determined by enzymatic cоlorimetric method. The study found that increasing concentration of plasma HC is associated with intensity of hyperlipidemia, and hyperhomocysteinemia severity prevails over the changes in the lipid profile components. During AIS a significant increase in the level of VEGF in the blood was observed, indicating the presence of vascular accident and activation of angiogenesis. Severity of vascular endothelial lesions is associated with the degree of increasing concentration VEGF that appears most significant in patients with severe AIS.

Keywords: , , ,

References:

  1. Ciaccio M, Bivona G, Bellia C. Therapeutical approach to plasma homocysteine and cardiovascular risk reduction. Ther Clin Risk Manag. 2008 Feb;4(1):219-24. PubMed, PubMedCentral, CrossRef
  2. Williams KT, Schalinske KL. Homocysteine metabolism and its relation to health and disease. Biofactors. 2010 Jan-Feb;36(1):19-24. PubMed, CrossRef
  3. Dietrich-Muszalska A, Malinowska J, Olas B, Głowacki R, Bald E, Wachowicz B, Rabe-Jabłońska J. The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochem Res. 2012 May;37(5):1057-62. PubMed, PubMedCentral, CrossRef
  4. Schaffer A, Verdoia M, Cassetti E, Marino P, Suryapranata H, De Luca G. Relationship between homocysteine and coronary artery disease. Results from a large prospective cohort study. Thromb Res. 2014 Aug;134(2):288-93.  PubMed, CrossRef
  5. Bostom AG, Selhub J. Homocysteine and arteriosclerosis: subclinical and clinical disease associations. Circulation. 1999 May 11;99(18):2361-3. PubMed, CrossRef
  6. Liu H, Yang M, Li GM, Qiu Y, Zheng J, Du X, Wang JL, Liu RW. The MTHFR C677T polymorphism contributes to an increased risk for vascular dementia: a meta-analysis. J Neurol Sci. 2010 Jul 15;294(1-2):74-80. PubMed, CrossRef
  7. Baños-González MA, Anglés-Cano E, Cardoso-Saldaña G, Peña-Duque MA, Martínez-Ríos MA, Valente-Acosta B, González-Pacheco H, de la Peña-Díaz A. Lipoprotein(a) and homocysteine potentiate the risk of coronary artery disease in male subjects. Circ J. 2012;76(8):1953-7.  PubMed, CrossRef
  8. Blacher J, Benetos A, Kirzin J, Malmejac A, Guize L, Safar M. Relation of plasma homocysteine to cerebrovascular mortality in a French population. Am J Cardiol. 2002; 90(6): 591-595.  CrossRef
  9. Ford AH, Flicker L, Alfonso H, Hankey GJ, Norman PE, van Bockxmeer FM, Almeida OP. Plasma homocysteine and MTHFRC677T polymorphism as risk factors for incident dementia. J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):70-5.  PubMed, CrossRef
  10. Kumakura H, Fujita K, Kanai H, Araki Y, Hojo Y, Kasama S, Iwasaki T, Ichikawa S, Nakashima K, Minami K. High-sensitivity C-reactive Protein, Lipoprotein(a) and Homocysteine are Risk Factors for Coronary Artery Disease in Japanese Patients with Peripheral Arterial Disease. J Atheroscler Thromb. 2015;22(4):344-54.  PubMed, CrossRef
  11. Chi OZ, Hunter C, Liu X, Weiss HR. Effects of VEGF and nitric oxide synthase inhibition on blood-brain barrier disruption in the ischemic and non-ischemic cerebral cortex. Neurol Res. 2005 Dec;27(8):864-8.  PubMed, CrossRef
  12. Hansen TM, Moss AJ, Brindle NP. Vascular endothelial growth factor and angiopoietins in neurovascular regeneration and protection following stroke. Curr Neurovasc Res. 2008 Nov;5(4):236-45.  PubMed, CrossRef
  13. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol. 2006 Feb;290(2):L209-21.  PubMed, CrossRef
  14. Narasimhan P, Liu J, Song YS. VEGF stimulates the ERK 1/2 signaling pathway and apoptosis in cerebral endothelial cells after ischemic conditions. Stroke. 2009; 40(4): 1467-1473.  CrossRef
  15. Ma Y, Qu Y, Fei Z. Vascular endothelial growth factor in cerebral ischemia. J Neurosci Res. 2011 Jul;89(7):969-78. PubMed, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.